Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: ABT-510, Abbott.

Johan R Westphal1

  • 1Radboud University Medical Center, Department of Pathology, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. J.Westphal@obgyn.umcn.nl

Current Opinion in Molecular Therapeutics
|October 8, 2004
PubMed
Summary

ABT-510, an angiogenesis inhibitor, is being developed as a potential treatment for solid tumors. This small peptide is currently in phase II clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complete protection against cryodamage of cryopreserved whole bovine and human ovaries using DMSO as a cryoprotectant.

Journal of assisted reproduction and genetics·2017
Same author

Clinically applied procedures for human ovarian tissue cryopreservation result in different levels of efficacy and efficiency.

Journal of assisted reproduction and genetics·2016
Same author

Noninvasive Detection of Metastases and Follicle Density in Ovarian Tissue Using Full-Field Optical Coherence Tomography.

Clinical cancer research : an official journal of the American Association for Cancer Research·2016
Same author

Status of sperm morphology assessment: an evaluation of methodology and clinical value.

Fertility and sterility·2014
Same author

Unknown risk of the reintroduction of malignant cells in a Danish cohort of women autotransplanted with ovarian tissue.

Fertility and sterility·2011
Same author

Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators.

BMC cancer·2006

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Angiogenesis is crucial for solid tumor growth and metastasis.
  • Thrombospondin-1 (TSP-1) is a natural inhibitor of angiogenesis.
  • Developing synthetic mimetics of TSP-1 offers a therapeutic strategy.

Purpose of the Study:

  • To evaluate the potential of ABT-510, a novel thrombospondin-1 mimetic, as an anti-cancer agent.
  • To assess the safety and efficacy of ABT-510 in patients with solid tumors.

Main Methods:

  • ABT-510 is a small peptide designed to inhibit angiogenesis.
  • The compound is under development by Abbott Laboratories.
  • Clinical trials are being conducted to evaluate its therapeutic potential.

Main Results:

  • ABT-510 is an angiogenesis inhibitor.
  • It is being investigated for the treatment of solid tumors.
  • Phase II clinical trials are currently underway.

Conclusions:

  • ABT-510 represents a promising therapeutic candidate for solid tumors.
  • Further clinical evaluation is warranted to establish its role in cancer treatment.

Related Experiment Videos